| rivastigmine / Generic mfg. |
2005-004909-29: Satunnaistettu, kaksoissokkoutettu, lumekontrolloitu yhdessä keskuksessa toteutettu tutkimus rinnakkaisilla ryhmillä rivastigmiinin vaikutuksesta MS-tautiin liittyvän fatiikin aivomekanismeihin |
|
|
| Ongoing | 4 | 32 | Europe | Exelon 3,0 mg, Exelon 3,0 mg | Juhani Ruutiainen | Multippeliskleroosia sairastavat potilaat ja terveet vapaaehtoiset kontrollihenkilöt. | | | | |
2006-004435-30: Protocol of study for the evaluation of the efficacy of rivastigmine on cognitive and behavioural disorders, following traumatic brain injury TBI in chronic patients. |
|
|
| Ongoing | 4 | 12 | Europe | EXELON 56CPS 1,5MG, EXELON 56CPS 1,5MG | FONDAZIONE SANTA LUCIA | Patients with cognitive and behavioural disorders following severe TBI and other severe acquired brain injury Glasgow Coma Scale GCS lower or equal 8 | | | | |
2017-000569-61: Comparison of therapeutic strategies with Cholinesterase Inhibitors: stop or still (SOS) trial |
|
|
| Not yet recruiting | 4 | 1205 | Europe | Donepezil, Galantamine, Rivastigmine, Donepezil, N06DA04, N06DA03, Coated tablet, Prolonged-release capsule, Capsule, ARICEPT, REMINYL, RIVASTIGMINE | CHU de Bordeaux, DGOS PHRC N 2016 | Alzheimer disease Maladie d'Alzheimer, Diagnosis of probable or possible AD, defined according to the NINCDS-ARDRA criteria cMild to moderate stage, defined by a MMSE score above 15 at the time of pré-inclusion Nouveau cas de Maladie d'AlzheimerDiagnostic de MA probable ou possible définie selon les critères NINCDS-ARDRA, Diseases [C] - Nervous System Diseases [C10] | | | | |
ChiCTR2100052254: Research on the Intervention Effect of Western Medicine on Preclinical AD: a Randomized Controlled Trial. |
|
|
| Recruiting | 4 | 192 | | Take 971 Targeting Aβ Manno-oligosaccharide Diacid Capsules orally ;Take rivastigmine orally ;Take placebo group orally | Xuanwu Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University, The National Key Research and Development Project of China (grant number 2018YFC1315204) | Alzheimer's disease | | | | |
| Recruiting | 4 | 10000 | | Rivastigmine Bitartrate Tablets | Beijing Yuanxin Technology Group Co., Ltd.; Wanquan Wante Pharmaceutical Jiangsu Co., Ltd., Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. | Alzheimer's disease and dementia | | | | |
NCT02670161: Quality Improvement and Practice Based Research in Neurology Using the EMR |
|
|
| Enrolling by invitation | 4 | 3300 | NA | Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description), (too many characters to list in this field; see Intervention Description) | NorthShore University HealthSystem | Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke | 12/25 | 12/26 | | |
NCT03454646: Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL) |
|
|
| Not yet recruiting | 4 | 1205 | Europe | cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine) | University Hospital, Bordeaux | Alzheimer Disease, Cholinesterase Inhibitors | 04/27 | 09/27 | | |
RIVA-PSP, NCT02839642: Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy |
|
|
| Completed | 3 | 106 | Europe | Rivastigmine, Placebo | Assistance Publique Hopitaux De Marseille | Progressive Supranuclear Palsy (PSP) | 06/22 | 11/22 | | |
NCT05564169: Masitinib in Patients With Mild to Moderate Alzheimer's Disease |
|
|
| Not yet recruiting | 3 | 600 | Europe | Placebo, Placebo Oral Tablet, Masitinib (4.5), AB1010, Standard of care | AB Science | Alzheimer Disease | 12/26 | 12/26 | | |
2008-008896-32: Memory, Ageing, and the Cholinergic System a combined fMRI and PET study |
|
|
| Ongoing | 2 | 40 | Europe | N-[C-11]-Methylpiperidin-4-yl-acetate, C11-MP4A, Capsule, Solution for injection, Exelon | University of Cologne | Patients with mild cognitive impairment (MCI) (50-80 years), who are at greater risk of developing alzheimer's dementia will be recruited in the present study and will be compared to an age-matched group of healthy subjects (50-80 years). | | | | |
2004-000507-17: Effectiveness of rivastigmine treatment in post-stroke patients with right brain damage and unilateral spatial neglect |
|
|
| Ongoing | 2 | 20 | Europe | Rivastigmine, NA, | FONDAZIONE SANTA LUCIA | Improvement of unilateral spatial neglect and functional status in right brain damaged patients | | | | |
| Not yet recruiting | 2 | 42 | US | Rivastigmine, Placebo | Washington University School of Medicine, American Academy of Clinical Toxicology | Anticholinergic Toxicity | 07/26 | 07/26 | | |
| Not yet recruiting | 2 | 42 | US | Rivastigmine, Placebo | Washington University School of Medicine, American Academy of Clinical Toxicology | Anticholinergic Toxicity | 07/26 | 07/26 | | |
NCT04366518: Toward a Computationally-Informed, Personalized Treatment for Hallucinations |
|
|
| Recruiting | 1 | 35 | US | Rivastigmine Capsule, Scopolamine, Placebo Capsule, Placebo Patch | Yale University, National Institute of Mental Health (NIMH) | Hallucinations, Auditory, Psychosis | 08/24 | 08/24 | | |
NCT04962841: Nutraceuticals and Drug Treatment in Frail Older Adults |
|
|
| Recruiting | N/A | 485 | Europe | Nutraceuticals, empaglifozin, nebivolol, sertraline, rivastigmine, metformin, ramipril, amlodipine | University of Campania "Luigi Vanvitelli" | Frailty | 07/21 | 04/23 | | |
| Recruiting | N/A | 14 | US | BrightGo cognitive training, Gamification for cognitive therapy, Standard of Care medication for early Alzheimer's Disease, Aricept 10 mg daily or Exelon 9.5 mg patch | Bright Cloud International Corp, National Institute on Aging (NIA), Rutgers, The State University of New Jersey | Alzheimer Disease, Healthy Aging | 12/22 | 02/23 | | |